Top

Published in:

Open Access 01-12-2023 | Clopidogrel | Research

miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute coronary syndrome

Authors: Zhen-Zhen Mo, Zhen Yuan, Yuan-Yuan Peng, Wan-Lu Zhou, Wei Dai, Guo Wang, Jie Tang, Wei Zhang, Bi-Lian Chen

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

Bleeding is a major adverse event during clopidogrel treatment in patients with acute coronary syndrome (ACS). However, the potential mechanism affecting bleeding among individuals is unclear. Herein, we investigated the involvement of CYP2C19*2 and CYP2C19*3, as well as 10 miRNA polymorphisms, in bleeding in Chinese patients with ACS during the first year of clopidogrel treatment. The miR-6076 rs1463411 G polymorphism was significantly associated with the risk of bleeding (P < 0.001), and the rs1463411 GT + GG genotype significantly increased the risk of bleeding (adjusted odds ratio, 6.09; 95% confidence interval, 1.09–34.0; P < 0.001). Dual luciferase assay showed that miR-6076 significantly decreased the mRNA expression of P2RY12 (P < 0.05). P2RY12 mRNA and protein levels were significantly lower in cells transfected with miR-6076-G than in cells transfected with miR-6076-T (P < 0.05). The findings indicate that miR-6076 targets P2RY12 mRNA and that miR-6076 rs1463411 T/G polymorphisms differentially regulate P2RY12 mRNA and protein levels in cells. rs1463411 G polymorphism may increase the risk of bleeding during clopidogrel treatment in patients with ACS.

Available only for authorised users

Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2016;68:1082–115. https://doi.org/10.1161/CIR.0000000000000404.CrossRefPubMed

Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57. https://doi.org/10.1056/NEJMoa0904327.CrossRefPubMed

Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15. https://doi.org/10.1056/NEJMoa0706482.CrossRefPubMed

Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607–21. https://doi.org/10.1016/S0140-6736(05)67660-X.CrossRefPubMed

Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527–33. https://doi.org/10.1016/S0140-6736(01)05701-4.CrossRefPubMed

Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502. https://doi.org/10.1056/NEJMoa010746.CrossRefPubMed

Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381:1621–31. https://doi.org/10.1056/NEJMoa1907096.CrossRefPubMed

Paré G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363:1704–14. https://doi.org/10.1056/NEJMoa1008410.CrossRefPubMed

Saiz-Rodríguez M, Belmonte C, Caniego JL, et al. Influence of CYP450 enzymes, CES1, PON1, ABCB1, and P2RY12 polymorphisms on clopidogrel response in patients subjected to a percutaneous neurointervention. Clin Ther. 2019;41:1199-212.e2. https://doi.org/10.1016/j.clinthera.2019.04.037.CrossRefPubMed

10.

Galeazzi R, Olivieri F, Spazzafumo L, et al. Clustering of ABCB1 and CYP2C19 genetic variants predicts risk of major bleeding and thrombotic events in elderly patients with acute coronary syndrome receiving dual antiplatelet therapy with aspirin and clopidogrel. Drugs Aging. 2018;35:649–56. https://doi.org/10.1007/s40266-018-0555-1.CrossRefPubMedPubMedCentral

11.

Novkovic M, Matic D, Kusic-Tisma J, Antonijevic N, Radojkovic D, Rakicevic L. Correction to: analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel. Eur J Clin Pharmacol. 2018;74:453. https://doi.org/10.1007/s00228-017-2401-5.CrossRefPubMed

12.

He L, Chen S, Li J, et al. Genetic and phenotypic frequency distribution of CYP2C9, CYP2C19 and CYP2D6 in over 3200 Han Chinese. Clin Exp Pharmacol Physiol. 2020;47:1659–63. https://doi.org/10.1111/1440-1681.13357.CrossRefPubMed

13.

Wang G, Lei H-P, Li Z, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol. 2009;65:281–5. https://doi.org/10.1007/s00228-008-0574-7.CrossRefPubMed

14.

Park M-W, Her SH, Kim H-S, et al. Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention. Pharmacogenet Genomics. 2013;23:558–62. https://doi.org/10.1097/FPC.0b013e328364eb92.CrossRefPubMed

15.

Li C, Zhang L, Wang H, et al. Gene variants in responsiveness to clopidogrel have no impact on clinical outcomes in Chinese patients undergoing percutaneous coronary intervention—a multicenter study. Int J Cardiol. 2017;240:360–6. https://doi.org/10.1016/j.ijcard.2017.03.015.CrossRefPubMed

16.

Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–105. https://doi.org/10.1101/gr.082701.108.CrossRefPubMedPubMedCentral

17.

Kaikkonen MU, Lam MTY, Glass CK. Non-coding RNAs as regulators of gene expression and epigenetics. Cardiovasc Res. 2011;90:430–40. https://doi.org/10.1093/cvr/cvr097.CrossRefPubMedPubMedCentral

18.

Zeller T, Keller T, Ojeda F, et al. Assessment of microRNAs in patients with unstable angina pectoris. Eur Heart J. 2014;35:2106–14. https://doi.org/10.1093/eurheartj/ehu151.CrossRefPubMed

19.

Liu C, Zhang F, Li T, et al. MirSNP, a database of polymorphisms altering miRNA target sites, identifies miRNA-related SNPs in GWAS SNPs and eQTLs. BMC Genomics. 2012;13:661. https://doi.org/10.1186/1471-2164-13-661.CrossRefPubMedPubMedCentral

20.

Zhou W-L, Mo Z-Z, Xiao F-Y, et al. microRNA-605 rs2043556 polymorphisms affect clopidogrel therapy through modulation of CYP2B6 and P2RY12 in acute coronary syndrome patients. Platelets. 2020;31:897–905. https://doi.org/10.1080/09537104.2019.1696455.CrossRefPubMed

21.

Cannon CP, Brindis RG, Chaitman BR, et al. 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the american college of cardiology foundation/american heart association task force on clinical data standards (writing committee to develop acute coronary syndromes and coronary artery disease clinical data standards). Crit Pathw Cardiol. 2013;12:65–105. https://doi.org/10.1161/CIR.0b013e3182831a11.CrossRefPubMed

22.

Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123:2736–47. https://doi.org/10.1161/CIRCULATIONAHA.110.009449.CrossRefPubMed

23.

Zhu L-P, Zhou J-P, Zhang J-X, et al. MiR-15b-5p regulates collateral artery formation by targeting AKT3 (protein kinase B-3). Arterioscler Thromb Vasc Biol. 2017;37:957–68. https://doi.org/10.1161/ATVBAHA.116.308905.CrossRefPubMed

24.

Shi Y, Zha J, Zuo M, Yan Q, Song H. Long noncoding RNA CHL1-AS1 promotes cell proliferation and migration by sponging miR-6076 to regulate CHL1 expression in endometrial cancer. J Cell Biochem. 2020;121:2655–63. https://doi.org/10.1002/jcb.29486.CrossRefPubMed

25.

Zhan X, Wu W, Han B, et al. Hsa-miR-196a2 functional SNP is associated with severe toxicity after platinum-based chemotherapy of advanced nonsmall cell lung cancer patients in a Chinese population. J Clin Lab Anal. 2012;26:441–6. https://doi.org/10.1002/jcla.21544.CrossRefPubMedPubMedCentral

26.

Andre P, Delaney SM, LaRocca T, et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest. 2003;112:398–406. https://doi.org/10.1172/JCI17864.CrossRefPubMedPubMedCentral

27.

Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest. 2001;107:1591–8. https://doi.org/10.1172/JCI12242.CrossRefPubMedPubMedCentral

28.

Houston BA, Schneider ALC, Vaishnav J, et al. Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. J Heart Lung Transplant. 2017;36:380–5. https://doi.org/10.1016/j.healun.2016.12.016.CrossRefPubMed

29.

Biswas M, Kali SK. Association of CYP2C19 loss-of-function alleles with major adverse cardiovascular events of clopidogrel in stable coronary artery disease patients undergoing percutaneous coronary intervention: Meta-analysis. Cardiovasc Drugs Ther. 2021;35:1147–59. https://doi.org/10.1007/s10557-021-07142-w.CrossRefPubMed

Title: miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute coronary syndrome
Authors: Zhen-Zhen Mo
Zhen Yuan
Yuan-Yuan Peng
Wan-Lu Zhou
Wei Dai
Guo Wang
Jie Tang
Wei Zhang
Bi-Lian Chen
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Clopidogrel
Acute Coronary Syndrome
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-023-01068-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute coronary syndrome

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

MRPL48 is a novel prognostic and predictive biomarker of hepatocellular carcinoma

LncRNA MAFG-AS1 is involved in human cancer progression

Intravascular laser irradiation of blood as novel migraine treatment: an observational study

A novel stop-gain pathogenic variant in the KCNQ1 gene causing long QT syndrome 1

Role of crescents for lupus nephritis in clinical, pathological and prognosis: a single-center retrospective cohort study

Minimal-access video-assisted retroperitoneal and/or transperitoneal debridement (VARTD) in the management of infected walled-off pancreatic necrosis with deep extension: initial experience from a prospective single-arm study